Kynan Feeney

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly, Jaffer A. Ajani, Thomas Zander et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Surgery +14

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler et al. · Nature · 2022 · 442 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, Navesh Sharma, Volker Heinemann et al. · The Lancet Oncology · 2017 · 398 citations · Full text

Medicine, Oncology, Radiation Oncology +17

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu et al. · Journal of Thoracic Oncology · 2021 · 322 citations · Full text

Pharmacy, Oncology, Pharmacology +17